These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 30589027)

  • 21. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
    Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
    J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
    Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
    J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.
    Lin Q; Liu YE; Ren XC; Wang N; Chen XJ; Wang DY; Zong J; Peng Y; Guo ZJ; Hu J
    Radiat Oncol; 2013 Aug; 8(1):201. PubMed ID: 23957889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
    Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
    BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
    Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy 
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
    Grimm SA; Marymont M; Chandler JP; Muro K; Newman SB; Levy RM; Jovanovic B; McCarthy K; Raizer JJ
    J Neurooncol; 2012 Nov; 110(2):237-43. PubMed ID: 22875709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme.
    Reddy K; Gaspar LE; Kavanagh BD; Chen C
    J Med Imaging Radiat Oncol; 2014 Dec; 58(6):714-21. PubMed ID: 24975917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas.
    Cho KH; Kim JY; Lee SH; Yoo H; Shin SH; Moon SH; Kim TH; Shin KH; Yoon M; Lee DH; Pyo HR
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):390-7. PubMed ID: 20097489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
    Dhermain F
    Chin J Cancer; 2014 Jan; 33(1):16-24. PubMed ID: 24384237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accelerated hypofractionated adjuvant whole breast radiation with simultaneous integrated boost using volumetric modulated arc therapy for early breast cancer: A phase I/II dosimetric and clinical feasibility study from a tertiary cancer care centre of India.
    Mondal D; Julka PK; Sharma DN; Jana M; Laviraj MA; Deo SV; Roy S; Guleria R; Rath GK
    J Egypt Natl Canc Inst; 2017 Mar; 29(1):39-45. PubMed ID: 28343538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five-year survival outcomes of intensity-modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) using forward IMRT or Tomotherapy for breast cancer.
    Lee HH; Chen CH; Luo KH; Chuang HY; Huang CJ; Cheng YK; Chen F; Kuo SH; Huang MY
    Sci Rep; 2020 Mar; 10(1):4342. PubMed ID: 32152428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maximum surgical resection and adjuvant intensity-modulated radiotherapy with simultaneous integrated boost for skull base chordoma.
    Kim JW; Suh CO; Hong CK; Kim EH; Lee IJ; Cho J; Lee KS
    Acta Neurochir (Wien); 2017 Oct; 159(10):1825-1834. PubMed ID: 27502775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
    Tsien CI; Brown D; Normolle D; Schipper M; Piert M; Junck L; Heth J; Gomez-Hassan D; Ten Haken RK; Chenevert T; Cao Y; Lawrence T
    Clin Cancer Res; 2012 Jan; 18(1):273-9. PubMed ID: 22065084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between Reirradiation by Stereotactic Body Radiation Therapy and Moderately Hypofractionated Radiotherapy in Combination with Temozolomide for Treatment of Recurrent High Grade Glioma.
    Saad E; Abdelwahed M; Moussa R; Abdulla M
    Asian Pac J Cancer Prev; 2024 Jul; 25(7):2499-2507. PubMed ID: 39068585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trial.
    Izzuddeen Y; Gupta S; Haresh KP; Sharma D; Giridhar P; Rath GK
    J Neurooncol; 2020 Jan; 146(1):91-95. PubMed ID: 31728883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma in Chinese population: A single institution experience.
    Xu Y; Wang Z; Liu G; Zheng X; Wang Y; Feng W; Lai X; Zhou X; Li P; Ma H; Wang J; Hu X; Chen M
    J Cancer Res Ther; 2016 Oct; 12(Supplement):82-88. PubMed ID: 27721262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma.
    Lertbutsayanukul C; Prayongrat A; Kannarunimit D; Chakkabat C; Netsawang B; Kitpanit S
    Strahlenther Onkol; 2018 May; 194(5):375-385. PubMed ID: 29302704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment outcomes and dose-volume histogram analysis of simultaneous integrated boost method for malignant gliomas using intensity-modulated radiotherapy.
    Nakamatsu K; Suzuki M; Nishimura Y; Kanamori S; Koike R; Shibata T; Shintani N; Okumura M; Okajima K; Akai F
    Int J Clin Oncol; 2008 Feb; 13(1):48-53. PubMed ID: 18307019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.